Bortezomib
- Generic Name
- Bortezomib
- Brand Names
- Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
- Drug Type
- Small Molecule
- Chemical Formula
- C19H25BN4O4
- CAS Number
- 179324-69-7
- Unique Ingredient Identifier
- 69G8BD63PP
- Background
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib.
Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.
- Indication
Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.
- Associated Conditions
- Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
- Associated Therapies
- -
Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2013-03-26
- Last Posted Date
- 2019-08-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 955
- Registration Number
- NCT01818752
- Locations
- 🇺🇸
California Cancer Associates for Research & Excellence, Inc. (cCARE), Fresno, California, United States
🇨🇳Guangdong General Hospital, Guangzhou, Guangdong, China
🇦🇺The Alfred Hospital, Melbourne, Victoria, Australia
A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma
- First Posted Date
- 2013-02-28
- Last Posted Date
- 2013-05-16
- Lead Sponsor
- Johnson & Johnson Taiwan Ltd
- Target Recruit Count
- 14
- Registration Number
- NCT01801436
A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy
- Conditions
- Interventions
- First Posted Date
- 2013-02-20
- Last Posted Date
- 2021-08-02
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 66
- Registration Number
- NCT01794507
- Locations
- 🇺🇸
University of Arizona Cancer Center - North Campus /ID# 117876, Tucson, Arizona, United States
🇺🇸Mayo Clinic /ID# 121495, Jacksonville, Florida, United States
🇦🇺Peter MacCallum Cancer Ctr /ID# 79553, Melbourne, Victoria, Australia
Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM)
- Conditions
- Interventions
- First Posted Date
- 2013-02-04
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT01782963
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Safety and Efficacy of Desensitization Therapy in Sensitized Participants Awaiting Heart Transplantation
- Conditions
- Interventions
- First Posted Date
- 2013-01-16
- Last Posted Date
- 2015-11-11
- Target Recruit Count
- 2
- Registration Number
- NCT01769443
- Locations
- 🇺🇸
University of Utah, Salt Lake City, Utah, United States
🇺🇸University of California at San Francisco, San Francisco, California, United States
🇺🇸Yale New Haven Hospital, New Haven, Connecticut, United States
Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2013-01-16
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 18
- Registration Number
- NCT01769209
- Locations
- 🇺🇸
Stanford University, School of Medicine, Stanford, California, United States
Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2012-12-21
- Last Posted Date
- 2017-07-18
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 138
- Registration Number
- NCT01754389
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Insitute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia
- First Posted Date
- 2012-11-29
- Last Posted Date
- 2021-02-24
- Lead Sponsor
- Joseph Tuscano
- Target Recruit Count
- 25
- Registration Number
- NCT01736943
- Locations
- 🇺🇸
University of California Comprehensive Cancer Center, Sacramento, California, United States
Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2012-11-28
- Last Posted Date
- 2023-06-06
- Lead Sponsor
- Celgene
- Target Recruit Count
- 559
- Registration Number
- NCT01734928
- Locations
- 🇺🇸
Western Kentucky Hematology and Oncology Group, PSC, Paducah, Kentucky, United States
🇺🇸Local Institution - 132, Bangor, Maine, United States
🇺🇸St. Agnes - Medical Center, Baltimore, Maryland, United States
First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD
- Conditions
- Interventions
- First Posted Date
- 2012-11-19
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 18
- Registration Number
- NCT01728259
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.